APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Assisted Reproductive Technologies Medications

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Assisted Reproductive Technologies Medications Market Analysis and Forecast 2026-2032

Report ID 173967690221 December 2025194 pages

Choose your research edition.

Industry ResearchAssisted Reproductive Technologies Medications Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Assisted Reproductive Technologies Medications Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Assisted Reproductive Technologies Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Assisted Reproductive Technologies Medications Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Assisted Reproductive Technologies Medications Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Assisted Reproductive Technologies Medications market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Assisted Reproductive Technologies Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Assisted Reproductive Technologies Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Assisted Reproductive Technologies Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Assisted Reproductive Technologies Medications is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Assisted Reproductive Technologies Medications include Zhejiang Xianju, Merck Serono, Livzon Pharmaceutical, Changchun GeneScience, Hybio Pharmaceutical, Solvay, Organon, Ipsen and Ferring, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Assisted Reproductive Technologies Medications, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Assisted Reproductive Technologies Medications, also provides the revenue of main regions and countries. Of the upcoming market potential for Assisted Reproductive Technologies Medications, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Assisted Reproductive Technologies Medications revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Assisted Reproductive Technologies Medications market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Assisted Reproductive Technologies Medications revenue, projected growth trends, production technology, application and end-user industry.

Assisted Reproductive Technologies Medications Segment by Company

Zhejiang Xianju

Merck Serono

Livzon Pharmaceutical

Changchun GeneScience

Hybio Pharmaceutical

Solvay

Organon

Ipsen

Ferring

Besins

Assisted Reproductive Technologies Medications Segment by Type

Ovulation Stimulation Drugs

Luteal Support Medications

Down-Regulation Drugs

Ovulation Inducing Drugs

Assisted Reproductive Technologies Medications Segment by Application

Specialty & Retail Pharmacy

Hospital Pharmacy

Online Pharmacy

Assisted Reproductive Technologies Medications Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Assisted Reproductive Technologies Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Assisted Reproductive Technologies Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Assisted Reproductive Technologies Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Assisted Reproductive Technologies Medications in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Assisted Reproductive Technologies Medications company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Assisted Reproductive Technologies Medications revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Assisted Reproductive Technologies Medications Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Ovulation Stimulation Drugs Major Player Table 3. Luteal Support Medications Major Player Table 4. Down-Regulation Drugs Major Player Table 5. Ovulation Inducing Drugs Major Player Table 6. Global Assisted Reproductive Technologies Medications Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Specialty & Retail Pharmacy Major Player Table 8. Hospital Pharmacy Major Player Table 9. Online Pharmacy Major Player Table 10. Assisted Reproductive Technologies Medications Industry Trends Table 11. Assisted Reproductive Technologies Medications Industry Drivers Table 12. Assisted Reproductive Technologies Medications Industry Opportunities and Challenges Table 13. Assisted Reproductive Technologies Medications Industry Restraints Table 14. Global Assisted Reproductive Technologies Medications Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Assisted Reproductive Technologies Medications Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Assisted Reproductive Technologies Medications Market Share by Region (2021-2026) Table 17. Global Assisted Reproductive Technologies Medications Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Assisted Reproductive Technologies Medications Market Share by Region (2027-2032) Table 19. Global Assisted Reproductive Technologies Medications Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Assisted Reproductive Technologies Medications Revenue Market Share by Players (2021-2026) Table 21. Global Assisted Reproductive Technologies Medications Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Assisted Reproductive Technologies Medications Key Players Headquarters & Area Served Table 23. Global Assisted Reproductive Technologies Medications Players, Product Type & Application Table 24. Global Assisted Reproductive Technologies Medications Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Assisted Reproductive Technologies Medications by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Assisted Reproductive Technologies Medications Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Assisted Reproductive Technologies Medications Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Assisted Reproductive Technologies Medications Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Assisted Reproductive Technologies Medications Revenue Market Share by Type (2021-2026) Table 31. Global Assisted Reproductive Technologies Medications Revenue Market Share by Type (2027-2032) Table 32. Global Assisted Reproductive Technologies Medications Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Assisted Reproductive Technologies Medications Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Assisted Reproductive Technologies Medications Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Assisted Reproductive Technologies Medications Revenue Market Share by Application (2021-2026) Table 36. Global Assisted Reproductive Technologies Medications Revenue Market Share by Application (2027-2032) Table 37. Zhejiang Xianju Company Information Table 38. Zhejiang Xianju Business Overview Table 39. Zhejiang Xianju Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Zhejiang Xianju Assisted Reproductive Technologies Medications Product Portfolio Table 41. Zhejiang Xianju Recent Development Table 42. Merck Serono Company Information Table 43. Merck Serono Business Overview Table 44. Merck Serono Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Merck Serono Assisted Reproductive Technologies Medications Product Portfolio Table 46. Merck Serono Recent Development Table 47. Livzon Pharmaceutical Company Information Table 48. Livzon Pharmaceutical Business Overview Table 49. Livzon Pharmaceutical Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Livzon Pharmaceutical Assisted Reproductive Technologies Medications Product Portfolio Table 51. Livzon Pharmaceutical Recent Development Table 52. Changchun GeneScience Company Information Table 53. Changchun GeneScience Business Overview Table 54. Changchun GeneScience Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Changchun GeneScience Assisted Reproductive Technologies Medications Product Portfolio Table 56. Changchun GeneScience Recent Development Table 57. Hybio Pharmaceutical Company Information Table 58. Hybio Pharmaceutical Business Overview Table 59. Hybio Pharmaceutical Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Hybio Pharmaceutical Assisted Reproductive Technologies Medications Product Portfolio Table 61. Hybio Pharmaceutical Recent Development Table 62. Solvay Company Information Table 63. Solvay Business Overview Table 64. Solvay Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Solvay Assisted Reproductive Technologies Medications Product Portfolio Table 66. Solvay Recent Development Table 67. Organon Company Information Table 68. Organon Business Overview Table 69. Organon Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Organon Assisted Reproductive Technologies Medications Product Portfolio Table 71. Organon Recent Development Table 72. Ipsen Company Information Table 73. Ipsen Business Overview Table 74. Ipsen Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Ipsen Assisted Reproductive Technologies Medications Product Portfolio Table 76. Ipsen Recent Development Table 77. Ferring Company Information Table 78. Ferring Business Overview Table 79. Ferring Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Ferring Assisted Reproductive Technologies Medications Product Portfolio Table 81. Ferring Recent Development Table 82. Besins Company Information Table 83. Besins Business Overview Table 84. Besins Assisted Reproductive Technologies Medications Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Besins Assisted Reproductive Technologies Medications Product Portfolio Table 86. Besins Recent Development Table 87. North America Assisted Reproductive Technologies Medications Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Assisted Reproductive Technologies Medications Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Assisted Reproductive Technologies Medications Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Assisted Reproductive Technologies Medications Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Assisted Reproductive Technologies Medications Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Assisted Reproductive Technologies Medications Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Assisted Reproductive Technologies Medications Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Assisted Reproductive Technologies Medications Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Assisted Reproductive Technologies Medications Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Assisted Reproductive Technologies Medications Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Assisted Reproductive Technologies Medications Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Assisted Reproductive Technologies Medications Revenue by Country (US$ Million) & (2027-2032) Table 101. China Assisted Reproductive Technologies Medications Revenue by Type (2021-2026) & (US$ Million) Table 102. China Assisted Reproductive Technologies Medications Revenue by Type (2027-2032) & (US$ Million) Table 103. China Assisted Reproductive Technologies Medications Revenue by Application (2021-2026) & (US$ Million) Table 104. China Assisted Reproductive Technologies Medications Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Assisted Reproductive Technologies Medications Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Assisted Reproductive Technologies Medications Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Assisted Reproductive Technologies Medications Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Assisted Reproductive Technologies Medications Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Assisted Reproductive Technologies Medications Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Assisted Reproductive Technologies Medications Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Assisted Reproductive Technologies Medications Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Assisted Reproductive Technologies Medications Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Assisted Reproductive Technologies Medications Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Assisted Reproductive Technologies Medications Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Assisted Reproductive Technologies Medications Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Assisted Reproductive Technologies Medications Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Assisted Reproductive Technologies Medications Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Assisted Reproductive Technologies Medications Image Figure 2. Global Assisted Reproductive Technologies Medications Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Assisted Reproductive Technologies Medications Market Size Share 2021 VS 2025 VS 2032 Figure 4. Ovulation Stimulation Drugs Image Figure 5. Luteal Support Medications Image Figure 6. Down-Regulation Drugs Image Figure 7. Ovulation Inducing Drugs Image Figure 8. Global Assisted Reproductive Technologies Medications Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Assisted Reproductive Technologies Medications Market Size Share 2021 VS 2025 VS 2032 Figure 10. Specialty & Retail Pharmacy Image Figure 11. Hospital Pharmacy Image Figure 12. Online Pharmacy Image Figure 13. Global Assisted Reproductive Technologies Medications Market Size (US$ Million) & (2021-2032) Figure 14. Global Assisted Reproductive Technologies Medications Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Assisted Reproductive Technologies Medications Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Assisted Reproductive Technologies Medications Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Assisted Reproductive Technologies Medications Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Assisted Reproductive Technologies Medications Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Assisted Reproductive Technologies Medications Revenue Market Share by Type (2021-2032) Figure 21. Global Assisted Reproductive Technologies Medications Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Assisted Reproductive Technologies Medications Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Assisted Reproductive Technologies Medications Revenue Market Share by Application (2021-2032) Figure 24. North America Assisted Reproductive Technologies Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032) Figure 26. North America Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032) Figure 27. North America Assisted Reproductive Technologies Medications Revenue Share by Country (2021-2032) Figure 28. United States Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Assisted Reproductive Technologies Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032) Figure 33. Europe Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032) Figure 34. Europe Assisted Reproductive Technologies Medications Revenue Share by Country (2021-2032) Figure 35. Germany Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Assisted Reproductive Technologies Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032) Figure 45. China Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032) Figure 46. Asia Assisted Reproductive Technologies Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032) Figure 48. Asia Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032) Figure 49. Asia Assisted Reproductive Technologies Medications Revenue Share by Region (2021-2032) Figure 50. Japan Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Assisted Reproductive Technologies Medications Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032) Figure 58. SAMEA Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032) Figure 59. SAMEA Assisted Reproductive Technologies Medications Revenue Share by Country (2021-2032) Figure 60. Brazil Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Assisted Reproductive Technologies Medications Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Ovulation Stimulation Drugs
  • Luteal Support Medications
  • Down-Regulation Drugs
  • Ovulation Inducing Drugs
Applications
  • Specialty & Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy
Companies covered
  • Zhejiang Xianju
  • Merck Serono
  • Livzon Pharmaceutical
  • Changchun GeneScience
  • Hybio Pharmaceutical
  • Solvay
  • Organon
  • Ipsen
  • Ferring
  • Besins

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Assisted Reproductive Technologies Medications Market by Type
  3. 1.2.1 Global Assisted Reproductive Technologies Medications Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Ovulation Stimulation Drugs
  5. 1.2.3 Luteal Support Medications
  6. 1.2.4 Down-Regulation Drugs
  7. 1.2.5 Ovulation Inducing Drugs
  8. 1.3 Assisted Reproductive Technologies Medications Market by Application
  9. 1.3.1 Global Assisted Reproductive Technologies Medications Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Specialty & Retail Pharmacy
  11. 1.3.3 Hospital Pharmacy
  12. 1.3.4 Online Pharmacy
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Assisted Reproductive Technologies Medications Market Dynamics
  1. 2.1 Assisted Reproductive Technologies Medications Industry Trends
  2. 2.2 Assisted Reproductive Technologies Medications Industry Drivers
  3. 2.3 Assisted Reproductive Technologies Medications Industry Opportunities and Challenges
  4. 2.4 Assisted Reproductive Technologies Medications Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Assisted Reproductive Technologies Medications Market Perspective (2021-2032)
  2. 3.2 Global Assisted Reproductive Technologies Medications Growth Trends by Region
  3. 3.2.1 Global Assisted Reproductive Technologies Medications Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Assisted Reproductive Technologies Medications Market Size by Region (2021-2026)
  5. 3.2.3 Global Assisted Reproductive Technologies Medications Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Assisted Reproductive Technologies Medications Revenue by Players
  2. 4.1.1 Global Assisted Reproductive Technologies Medications Revenue by Players (2021-2026)
  3. 4.1.2 Global Assisted Reproductive Technologies Medications Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Assisted Reproductive Technologies Medications Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Assisted Reproductive Technologies Medications Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Assisted Reproductive Technologies Medications Key Players Headquarters & Area Served
  7. 4.4 Global Assisted Reproductive Technologies Medications Players, Product Type & Application
  8. 4.5 Global Assisted Reproductive Technologies Medications Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Assisted Reproductive Technologies Medications Market CR5 and HHI
  11. 4.6.3 2025 Assisted Reproductive Technologies Medications Tier 1, Tier 2, and Tier 3
5 Assisted Reproductive Technologies Medications Market Size by Type
  1. 5.1 Global Assisted Reproductive Technologies Medications Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Assisted Reproductive Technologies Medications Revenue by Type (2021-2032)
  3. 5.3 Global Assisted Reproductive Technologies Medications Revenue Market Share by Type (2021-2032)
6 Assisted Reproductive Technologies Medications Market Size by Application
  1. 6.1 Global Assisted Reproductive Technologies Medications Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Assisted Reproductive Technologies Medications Revenue by Application (2021-2032)
  3. 6.3 Global Assisted Reproductive Technologies Medications Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Zhejiang Xianju
  2. 7.1.1 Zhejiang Xianju Company Information
  3. 7.1.2 Zhejiang Xianju Business Overview
  4. 7.1.3 Zhejiang Xianju Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Zhejiang Xianju Assisted Reproductive Technologies Medications Product Portfolio
  6. 7.1.5 Zhejiang Xianju Recent Developments
  7. 7.2 Merck Serono
  8. 7.2.1 Merck Serono Company Information
  9. 7.2.2 Merck Serono Business Overview
  10. 7.2.3 Merck Serono Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck Serono Assisted Reproductive Technologies Medications Product Portfolio
  12. 7.2.5 Merck Serono Recent Developments
  13. 7.3 Livzon Pharmaceutical
  14. 7.3.1 Livzon Pharmaceutical Company Information
  15. 7.3.2 Livzon Pharmaceutical Business Overview
  16. 7.3.3 Livzon Pharmaceutical Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Livzon Pharmaceutical Assisted Reproductive Technologies Medications Product Portfolio
  18. 7.3.5 Livzon Pharmaceutical Recent Developments
  19. 7.4 Changchun GeneScience
  20. 7.4.1 Changchun GeneScience Company Information
  21. 7.4.2 Changchun GeneScience Business Overview
  22. 7.4.3 Changchun GeneScience Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Changchun GeneScience Assisted Reproductive Technologies Medications Product Portfolio
  24. 7.4.5 Changchun GeneScience Recent Developments
  25. 7.5 Hybio Pharmaceutical
  26. 7.5.1 Hybio Pharmaceutical Company Information
  27. 7.5.2 Hybio Pharmaceutical Business Overview
  28. 7.5.3 Hybio Pharmaceutical Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hybio Pharmaceutical Assisted Reproductive Technologies Medications Product Portfolio
  30. 7.5.5 Hybio Pharmaceutical Recent Developments
  31. 7.6 Solvay
  32. 7.6.1 Solvay Company Information
  33. 7.6.2 Solvay Business Overview
  34. 7.6.3 Solvay Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Solvay Assisted Reproductive Technologies Medications Product Portfolio
  36. 7.6.5 Solvay Recent Developments
  37. 7.7 Organon
  38. 7.7.1 Organon Company Information
  39. 7.7.2 Organon Business Overview
  40. 7.7.3 Organon Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Organon Assisted Reproductive Technologies Medications Product Portfolio
  42. 7.7.5 Organon Recent Developments
  43. 7.8 Ipsen
  44. 7.8.1 Ipsen Company Information
  45. 7.8.2 Ipsen Business Overview
  46. 7.8.3 Ipsen Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Ipsen Assisted Reproductive Technologies Medications Product Portfolio
  48. 7.8.5 Ipsen Recent Developments
  49. 7.9 Ferring
  50. 7.9.1 Ferring Company Information
  51. 7.9.2 Ferring Business Overview
  52. 7.9.3 Ferring Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ferring Assisted Reproductive Technologies Medications Product Portfolio
  54. 7.9.5 Ferring Recent Developments
  55. 7.10 Besins
  56. 7.10.1 Besins Company Information
  57. 7.10.2 Besins Business Overview
  58. 7.10.3 Besins Assisted Reproductive Technologies Medications Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Besins Assisted Reproductive Technologies Medications Product Portfolio
  60. 7.10.5 Besins Recent Developments
8 North America
  1. 8.1 North America Assisted Reproductive Technologies Medications Revenue (2021-2032)
  2. 8.2 North America Assisted Reproductive Technologies Medications Revenue by Type (2021-2032)
  3. 8.2.1 North America Assisted Reproductive Technologies Medications Revenue by Type (2021-2026)
  4. 8.2.2 North America Assisted Reproductive Technologies Medications Revenue by Type (2027-2032)
  5. 8.3 North America Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032)
  6. 8.4 North America Assisted Reproductive Technologies Medications Revenue by Application (2021-2032)
  7. 8.4.1 North America Assisted Reproductive Technologies Medications Revenue by Application (2021-2026)
  8. 8.4.2 North America Assisted Reproductive Technologies Medications Revenue by Application (2027-2032)
  9. 8.5 North America Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032)
  10. 8.6 North America Assisted Reproductive Technologies Medications Revenue by Country
  11. 8.6.1 North America Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Assisted Reproductive Technologies Medications Revenue by Country (2021-2026)
  13. 8.6.3 North America Assisted Reproductive Technologies Medications Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Assisted Reproductive Technologies Medications Revenue (2021-2032)
  2. 9.2 Europe Assisted Reproductive Technologies Medications Revenue by Type (2021-2032)
  3. 9.2.1 Europe Assisted Reproductive Technologies Medications Revenue by Type (2021-2026)
  4. 9.2.2 Europe Assisted Reproductive Technologies Medications Revenue by Type (2027-2032)
  5. 9.3 Europe Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032)
  6. 9.4 Europe Assisted Reproductive Technologies Medications Revenue by Application (2021-2032)
  7. 9.4.1 Europe Assisted Reproductive Technologies Medications Revenue by Application (2021-2026)
  8. 9.4.2 Europe Assisted Reproductive Technologies Medications Revenue by Application (2027-2032)
  9. 9.5 Europe Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032)
  10. 9.6 Europe Assisted Reproductive Technologies Medications Revenue by Country
  11. 9.6.1 Europe Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Assisted Reproductive Technologies Medications Revenue by Country (2021-2026)
  13. 9.6.3 Europe Assisted Reproductive Technologies Medications Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Assisted Reproductive Technologies Medications Revenue (2021-2032)
  2. 10.2 China Assisted Reproductive Technologies Medications Revenue by Type (2021-2032)
  3. 10.2.1 China Assisted Reproductive Technologies Medications Revenue by Type (2021-2026)
  4. 10.2.2 China Assisted Reproductive Technologies Medications Revenue by Type (2027-2032)
  5. 10.3 China Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032)
  6. 10.4 China Assisted Reproductive Technologies Medications Revenue by Application (2021-2032)
  7. 10.4.1 China Assisted Reproductive Technologies Medications Revenue by Application (2021-2026)
  8. 10.4.2 China Assisted Reproductive Technologies Medications Revenue by Application (2027-2032)
  9. 10.5 China Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Assisted Reproductive Technologies Medications Revenue (2021-2032)
  2. 11.2 Asia Assisted Reproductive Technologies Medications Revenue by Type (2021-2032)
  3. 11.2.1 Asia Assisted Reproductive Technologies Medications Revenue by Type (2021-2026)
  4. 11.2.2 Asia Assisted Reproductive Technologies Medications Revenue by Type (2027-2032)
  5. 11.3 Asia Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032)
  6. 11.4 Asia Assisted Reproductive Technologies Medications Revenue by Application (2021-2032)
  7. 11.4.1 Asia Assisted Reproductive Technologies Medications Revenue by Application (2021-2026)
  8. 11.4.2 Asia Assisted Reproductive Technologies Medications Revenue by Application (2027-2032)
  9. 11.5 Asia Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032)
  10. 11.6 Asia Assisted Reproductive Technologies Medications Revenue by Country
  11. 11.6.1 Asia Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Assisted Reproductive Technologies Medications Revenue by Country (2021-2026)
  13. 11.6.3 Asia Assisted Reproductive Technologies Medications Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Assisted Reproductive Technologies Medications Revenue (2021-2032)
  2. 12.2 SAMEA Assisted Reproductive Technologies Medications Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Assisted Reproductive Technologies Medications Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Assisted Reproductive Technologies Medications Revenue by Type (2027-2032)
  5. 12.3 SAMEA Assisted Reproductive Technologies Medications Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Assisted Reproductive Technologies Medications Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Assisted Reproductive Technologies Medications Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Assisted Reproductive Technologies Medications Revenue by Application (2027-2032)
  9. 12.5 SAMEA Assisted Reproductive Technologies Medications Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Assisted Reproductive Technologies Medications Revenue by Country
  11. 12.6.1 SAMEA Assisted Reproductive Technologies Medications Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Assisted Reproductive Technologies Medications Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Assisted Reproductive Technologies Medications Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst